Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse aggressive lymphoma.

Richard I Fisher1, Thomas P Miller, Owen A O'Connor

  • 1James B. Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2004
PubMed
Summary

Aggressive non-Hodgkin's lymphomas are increasingly curable. Advances in understanding disease heterogeneity and new therapies like CHOP/rituximab have established new standards of care for advanced diffuse large B-cell lymphoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance.

Cancer medicine·2026
Same author

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Leukemia & lymphoma·2026
Same author

Are CHOP-plus really CHOP-minus propositions in the treatment of PTCL? A comprehensive assessment of the strategy.

Blood advances·2026
Same author

Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.

Blood·2025
Same author

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.

British journal of haematology·2025
Same author

Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology.

CA: a cancer journal for clinicians·2025

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Aggressive non-Hodgkin's lymphomas (NHL) present significant treatment challenges due to disease heterogeneity.
  • Past clinical trials showed variable results, necessitating a deeper understanding of patient populations.
  • Recent molecular and clinical studies have improved disease classification for targeted therapies.

Purpose of the Study:

  • To review current standards of care for aggressive NHL.
  • To discuss emerging therapies and future directions in lymphoma treatment.
  • To highlight the impact of disease heterogeneity on clinical trial outcomes.

Main Methods:

  • Review of combination chemotherapy regimens, including CHOP and its modifications.
  • Analysis of Phase II and III clinical trial data for advanced and limited-stage aggressive NHL.

Related Experiment Videos

  • Examination of novel agents and treatment strategies for mantle cell lymphoma.

    • Main Results:

    • CHOP/rituximab is the established standard for advanced diffuse large B-cell lymphoma, improving survival.
    • Limited-stage aggressive NHL benefits from chemotherapy and radiotherapy, with ongoing research into novel agents.
    • Mantle cell lymphoma shows promise with new agents like bortezomib, though survival benefits are still under investigation.

    Conclusions:

    • Standard of care has advanced for advanced diffuse large B-cell lymphoma with CHOP/rituximab.
    • Further research is needed to address heterogeneity in limited-stage aggressive NHL and mantle cell lymphoma.
    • Novel therapeutic strategies offer hope for uniformly fatal malignancies and relapsed patients.